Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies
Fanny Pommeret, Johann Colomba, Camille Bigenwald, Ariane Laparra, S. Bockel, Arnaud Bayle, Jean‐Marie Michot, Thomas Hueso, Laurence Albigès, Pierre Tiberghien, Stéphane Marot, Aude Jary, Karine Lacombe, Fabrice Barlési, Frank Griscelli, Émeline Colomba
Topics & Concepts
MedicineInternal medicineViral loadCoronavirus disease 2019 (COVID-19)PlaceboSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clinical trialImmunologyPathologyHuman immunodeficiency virus (HIV)DiseaseAlternative medicineInfectious disease (medical specialty)COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchCOVID-19 and healthcare impacts